Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$8.60

0.00 (0.00%)

High$8.74
Low$8.47
Volume0
Market Cap$91,390,781

08/17/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $8.60 with a 52 week high of $21.59 and a 52 week low of $7.20.

Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update

08/14/17

Read More

Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients

08/07/17

Read More

Gemphire to Present at the Canaccord Genuity Growth Conference 2017

08/07/17

Read More


There are currently no events scheduled.